Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 3Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 87INDUSTRY 11OTHER_GOV 6UNKNOWN 1NIH 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 267Neoplasms 176Colorectal Neoplasms 133Stomach Neoplasms 107Uterine Cervical Neoplasms 95Carcinoma, Non-Small-Cell Lung 89Prostatic Neoplasms 82Lung Neoplasms 78Carcinoma, Hepatocellular 72Rectal Neoplasms 64Ovarian Neoplasms 54Esophageal Neoplasms 53Pancreatic Neoplasms 52Colonic Neoplasms 52Recurrence 43Multiple Myeloma 39Neoplasm Metastasis 38Head and Neck Neoplasms 37Endometrial Neoplasms 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Motor Activity 34Melanoma 33Polycystic Ovary Syndrome 32Lymphoma 32Urinary Bladder Neoplasms 31Leukemia, Myeloid, Acute 30Thyroid Neoplasms 29Small Cell Lung Carcinoma 28Nasopharyngeal Carcinoma 25Lymphoma, Non-Hodgkin 25

Interventions

pertuzumab 2Trastuzumab 2Docetaxel 2Carboplatin 2Epirubicin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER_GOV × Pathologic Complete Response × Clear all
NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
610 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
71 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT03539965 2018-05-31

TNBCbrazil

Instituto Nacional de Cancer, Brazil

Completed
239 enrolled
Breast

Pathologic Complete Response, Triple Negative Breast Neoplasms

NCT01830244 2017-07-02

Neonab

Barwon Health

Phase 2 Unknown
60 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡